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ABSTRACT
Cell proliferation, a main target in cancer therapy, is influenced by the
surrounding three-dimensional (3D) extracellular matrix (ECM). In vitro
drug screening is, thus, optimally performed under conditions in which
cells are grown (embedded or trapped) in dense 3D matrices, as these
most closely mimic the adhesive and mechanical properties of natural
ECM. Measuring cell proliferation under these conditions is, however,
technically more challenging compared with two-dimensional (2D)
culture and other ‘‘3D culture conditions,’’ such as growth on top of a
matrix (pseudo-3D) or in spongy scaffolds with large pore sizes. Con-
sequently, such measurements are only slowly applied on a wider scale.
To advance this, we report on the equal quality (dynamic range, back-
ground, linearity) of measuring the proliferation of cell layers embedded
in dense 3D matrices (collagen, Matrigel) compared with cells in 2D
culture using the easy (one-step) and in 2D well-validated, 2,3-bis-(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT)-
assay. The comparison stresses the differences in proliferation kinetics
and drug sensitivity of matrix-embedded cells versus 2D culture. Using
the specific cell-layer-embedded 3D matrix setup, quantitative mea-
surements of cell proliferation and cell invasion are shown to be possible
in similar assay conditions, and cytostatic, cytotoxic, and anti-invasive
drug effects can thus be reliably determined and compared in physio-
logically relevant settings. This approach in the 3D matrix holds promise
for improving early-stage, high-throughput drug screening, targeting
either highly invasive or highly proliferative subpopulations of cancers or
both.
INTRODUCTION
C
ell proliferation, survival, angiogenesis, and invasion form
major targets in anti-cancer therapy. Potentially bioactive
molecules are continuously being isolated from living
matter or synthesized de novo in the search for new ther-
apeutic cancer agents. Drugs or drug combinations that target
multiple aspects of this malignant process are an ultimate goal in
both first-line therapy and relapse prevention. The objective of
gaining reliable insights into the multifaceted potential of drugs
should preferably be incorporated in the design of early-stage
screening steps. Cell proliferation, survival, and invasion should
consequently be measured using similar conditions. Traditionally,
in vitro screening for antiproliferative or toxic effects is performed
on cells cultured on two-dimensional (2D) substrates.1–3 The pre-
dictability of clinical efficacy for hits identified in in vitro screening
using 2D cultures is, however, generally low,4 and it is suggested that
this could be increased by introducing a higher complexity in the
early screening steps, that is, by using more physiological ‘‘in vitro
three-dimensional (3D) culture’’ conditions.5 Indeed, cell-cell con-
tacts and cell-extracellular matrix (ECM) interactions, and their as-
sociated signaling, have been implicated not only in the invasive
process,6 but also in the cell proliferation.7–10 ‘‘In vitro 3D culture’’ is
an increasingly fashionable term, but it is—confusingly—used for
very diverse cell culture conditions displaying different levels of
complexity. First, it is used for cells grown in a pseudo-3D culture,
that is, on top of a natural matrix composed of ECM proteins.11–13
Second, the term 3D culture may indicate the cells grown on the
curved 2D surface presented by porous scaffolds, usually charac-
terized by a large surface area, high porosity, and a pore size
(*100 mm) that is typically much larger than the cell diameter and
that enables effective fluid transport.14,15 Last, the 3D culture is used
for cells grown fully encapsulated (embedded, trapped) within dense
3D matrices or hydrogels that have small pore sizes (as in natural
ECM) and that can either be synthetic or biological in composi-
tion.11,16,17 In this article, we specifically focus on the measurements
of cell proliferation of cancer cell lines embedded in dense 3D ma-
trices, in particular those composed of collagen or Matrigel. These
present a physiologically relevant topology as well as mechanical and
adhesive properties reminiscent of a native ECM to cells.16,18 More-
over, given their density, collagen gels and Matrigel display a matrix
fiber cross-linking degree and a pore size that is also found in tumor
micro-environments and are still most frequently used for in vitro
assaying of drug effects on cancer cell invasion.11,18,19 In addition,
these dense 3D matrices composed of natural ECM proteins can be
remodeled by the inherent ECM degradation properties of cells, a
process essential for cell differentiation, growth, and invasion.
ABBREVIATIONS: 2D, two-dimensional; 3D, three-dimensional; 5-FU, 5-fluorouracil; BSA, bovine serum albumin; dFUR, 5-Fluoro-20-deoxyuridine; DMEM, Dulbecco’s
modified Eagle’s medium; D-PBS, Dulbecco’s Phosphate-Buffered Saline; ECM, extracellular matrix; FCS, fetal calf serum; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; PAK, p21-activated kinase; ROCK, Rho-associated protein kinase; S/B, signal-to-background; SEM, standard error of the mean; S/N, signal-
to-noise; XTT, 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide.
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For cells grown on a 2D surface, diverse cell proliferation as-
says are available.20–25 These include the method using 2,3-bis-
(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide
(XTT), which is a second-generation water-soluble variant of the
tetrazolium salt 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT). It measures proliferation based on the meta-
bolic activity of the cells and is frequently used in 2D culture
conditions.26–31 Given the similar accessibility of cells grown in a
pseudo-3D culture or in porous or spongy 3D scaffolds compared with
that in 2D culture, the XTT-assay (and MTT-assay) has also already
been successfully applied for cells grown on top of ECM gels31,32 or on
the surface of porous ECM scaffolds.14,33–35 The use of XTT or other
methods that measure the proliferation of cells embedded in dense 3D
matrices is, however, still very limited and, in general, this approach is
only slowly gaining application on a wider scale, especially for higher
throughput analysis.36,37
The aim of this study was to provide a comprehensive report on the
high-quality applicability of the XTT-assay as an easy, one-step
procedure for measuring the proliferation of cells embedded as a
layer in dense 3D matrices. In this way, we aim at facilitating the
advance of cell proliferation measurements in physiologically more
relevant environments. The results show that the XTT-method26 can
be used with an equally high quality in dense 3D matrices (with
different densities) as in a 2D culture. We further demonstrate that
in vitro cell proliferation and antiproliferative effects induced by
drugs are indeed different in a dense 3D matrix compared with a 2D
culture. Moreover, in relation to the need of measuring the features of
cancer cells in a multifaceted manner, we validate the application of
the XTT-assay under a condition (including a relevant dense 3D
matrix) that is also compatible with measuring the invasive capacity.
Using selected drugs, we demonstrate that this may allow a more in-
depth in vitro characterization of potential anti-cancer drugs.
MATERIALS AND METHODS
Cell Lines
Human breast adenocarcinoma fibroblast-like MDA-MB-231
(ATCC: HTB-26) and human fibrosarcoma HT-1080 (ATCC: CCL-121)
were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco,
Invitrogen) supplemented with 10% heat-inactivated fetal calf
serum (FCS; Gibco), 20mM L-GlutaMaxI (Gibco), and 1% penicillin-
streptomycin (Gibco). Human mammary adenocarcinoma epithelial-
like MCF-7 (ATCC: HTB-22) were cultivated in a 1:1 ratio of DMEM/
F12 nutritional component HAM medium (HamF12; Gibco) supple-
mented with 10% heat-inactivated FCS (Gibco), 20mM L-GlutaMaxI
(Gibco), and 1% penicillin-streptomycin (Gibco). All the cells were
maintained at 37C in a humidified 5% CO2 atmosphere.
ECM Protein Handling: 3D Surface Coating
and Preparation of 3D Matrices
Rat-tail collagen type I (acid-extracted, nonpepsin treated) and
Matrigel were obtained from BD Biosciences. For obtaining a 2D
coating of monomeric collagen, the wells of a 96-well plate (NUNC;
Thermo Fisher Scientific) were incubated for 1 h at room temperature
with 100 mL of 40 mg/mL monomeric collagen in calcium and mag-
nesium containing Dulbecco’s Phosphate-Buffered Saline (D-PBS;
Gibco). The collagen solution for polymerization and 3D matrix
preparation consisted of 2mg/mL type I collagen, 1· MEM (Gibco),
and 8.3mMNaHCO3 in Hank’s Balanced Salt Solution (Gibco), and its
pH was adjusted to pH 7.4–8 with 1M NaOH. Matrigel was diluted at
1/2 or 1/5 with normal growth medium to a final concentration of
5mg/mL or 2mg/mL (based on an approximate concentration pro-
vided by the manufacturer). The collagen solution and Matrigel di-
lution were kept on ice until further use.
Experimental Setups: 2D Culture and 3D Matrix-Embedded
Cell Layer Culture
Cells were seeded in 96-well plates at a specified density. The cells
in ‘‘2D culture’’ were seeded in normal growth medium on top of a
monomeric collagen coating and maintained in the same medium. In
the 3D setup, cells are trapped as a cell layer in the ECM. To obtain this
‘‘3D matrix-embedded cell layer’’ (Fig. 1A, middle), in the first step,
the cells were seeded in normal growth medium on top of a thin layer
of either polymerized collagen or Matrigel (polymerization*15min
at 37C and 5% CO2) in a 96-well plate. After 2 h at 37C and 5% CO2
allowing cell adhesion and spreading, the growth medium was re-
moved, and the cells were overlaid with a second layer (40 mL) of the
collagen solution or Matrigel dilution. After polymerization (30min
at 37C and 5% CO2), 100 mL of the growth medium was added on top
of the 3D collagen I gel or Matrigel.
Cell Proliferation Assay in 2D and 3D
Cell Proliferation Kit II (XTT) (Roche) was used according to the
manufacturer’s protocol that was described for 2D cultures. In the 2D
cultures, 50 mL of the XTT labeling mixture was added to the 100 mL
of growth medium, whereas for the 3D matrix-embedded cells, 50 mL
of the XTT labeling mixture was added to the 100 mL of growth
medium present on top of the 40 mL matrix. The XTT labeling mixture
was added in parallel samples at 0 h (t0) (subsequent to cell adhesion
[2D] or polymerization of the matrix [3D]) and after a specified
number of hours of cell growth (tx). A set of blanks were included for
each condition. These do not contain cells and are treated identically
as the normal samples. Absorbance for both 2D and 3D matrix-em-
bedded cultures was measured at 3 h (or as specified) after XTT ad-
dition (see section on optimizing XTT incubation time in Results). Net
absorbances (A450–A620) were calculated. All conditions were per-
formed inmultiple replicates as specified. Per condition, the mean net
absorbance of all replicates at t0 and tx was background corrected (by
subtracting the mean of the blanks) and designated as At0 and Atx,
respectively. If not otherwise specified, the mean cell proliferation at
tx was expressed as a fold increase versus t0 (Atx/At0).
Table 1 describes the step-wise protocol that measures cell pro-
liferation in the 3D matrix-embedded cell layer culture.
Drug Treatment and Data Analysis
Cells, seeded at 10,000 (MDA-MB-231) or 5,000 (HT-1080) cells/
well, were treated for 48 h (MDA-MB-231) or 44 h (HT-1080) (time
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points chosen to be larger than the doubling times of the respective
cells, based on Figure 2) with y-27632 (Rho-associated protein ki-
nase [ROCK] inhibitor) (Calbiochem, Merck KGaA), IPA 3 (group I
p21-activated kinase [PAK] inhibitor) (Tocris Bioscience), or 5-
fluoro-20-deoxyuridine (dFUR) (Sigma-Aldrich). Overall, 1.33-fold
(100.125-fold) serial dilutions were prepared for each drug to obtain
dose-response curves leading to EC50 values. The starting concen-
tration varied for each drug, that is, 400 mM y-27632, 120 mM IPA 3,
and 90 mM 5-fluorouracil (5-FU). The inhibitors were administered at
time t0 to the ‘‘2D cultures’’ by replacing the growthmedium after cell
adhesion with drug-containing medium. In 3D matrix-embedded
cultures, the drugs were added at time t0 to the growth medium
overlaying the matrix while taking into account the volume of the
matrix to obtain the desired final drug concentration.
The proliferation fold at tx versus t0 was first calculated as the
ratio of the background subtracted net absorbances at time x versus
Fig. 1. XTT-based proliferation
measurement in 2D and 3D ma-
trix-embedded culture: optimiza-
tion of cell number. (A) Schematic
representation of experimental
setups: 2D culture (left), 3D
matrix-embedded cell layer (mid-
dle), and 3D matrix-embedded
mixed culture (right). (B, C) XTT-
based absorbance increases in
function of cell number. The net
absorbance (A450–620) is plotted;
error bars represent SEM. (B)
MDA-MB-231 and HT-1080 were
seeded at cell densities from
5,000 cells to 50,000 cells in 2D
culture (solid lines) or in a 3D
environment, that is, as a cell
layer in between two layers of
collagen (dashed lines); n = 2
(MDA-MB-231) or n = 4 (HT-1080).
Linear fitting on the data for cell
densities ranging from 5,000 to
25,000 (dotted line). (C)MDA-MB-
231 and HT-1080 cells seeded as a
layer in Matrigel (at 5mg/mL
[solid line] or 2mg/mL [dashed
line]) at cell densities from 5,000
cells up to 50,000 cells/well;
n = 4. Linear fitting on the data
corresponding to cell numbers
ranging from 5,000 to 20,000
(dotted line). (D) Phase-contrast
images of MDA-MB-231 cells see-
ded at 10,000 cells/well or 40,000
cells/well in a 2D culture (top) or
a 3D matrix-embedded cell layer
(bottom). Scale bar = 200 mm. (E)
MDA-MB-231 cells were seeded in
a 2D culture at cell densities
ranging from 5,000 to 100,000
cells and stained with DAPI. The
cell nuclei were counted and
plotted as cells/cm2 versus the
number of seeded cells. 2D, two-
dimensional; 3D, three-dimensional;
XTT, 2,3-bis-(2-methoxy-4-nitro-
5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide; SEM, standard
error of the mean.
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time zero (Atx/At0). Consequently, Atx/At0= 1 is indicative of a cyto-
static effect, and Atx/At0 < 1 indicates cytotoxicity (data points in red
in dose-response curves). Atx/At0 values were normalized by setting
untreated samples to 100% viability and blank samples (no cells) to
0% viability (maximal toxicity). We verified for the two cell lines and
for the 2D and 3D condition that these ‘‘maximal toxicity’’ samples
gave identical absorbance as alternative ‘‘0% viability’’ samples in
which the same number of cells are present as in the drug-treated
samples, but in which the cells were killed by treatment with 0.2%
Triton-X-100 (Sigma) before XTT-addition and measurement (100%
dead cells). Indeed, the maximal deviation in absorbance A between
these two ‘‘maximal toxicity’’ controls in
all conditions was DAtx = 0.021, whereas
DAtx between the controls and the 100%
viability samples was on average 0.885.
Using normalized Atx/At0 data, four-
parameter logistic or biphasic semi-log
dose-response curves were generated
using nonlinear regression to calculate
EC50 values (GraphPad Prism). The EC50
values represent the concentration of
the drug at which 50% of the effect is
obtained.
Invasion Assay
MDA-MB-231 cells were seeded as a 3D
matrix-embedded cell layer (collagen,
2mg/mL) as just described. A cell-free
area was, however, generated in the
middle of the well, according to the ORIS
cell invasion protocol (ORISTM; Platypus
Technologies), and the cells were allowed
to invade for 36 h in this cell-free central
zone. Phase-contrast time-lapse movies
were recorded for 36 h with an interval of
20min.
Assay Quality
Signal-to-background (S/B), signal-to-
noise (S/N), and Z-factors are determined
as described earlier.38 The dynamic range
of the assay in 2D culture or using the 3D
matrix-embedded cell layer setup was
derived from the comparison of the con-
trol and drug-treated cells. Untreated
MDA-MB-231 cells were used as a posi-
tive (maximal) signal, and MDA-MB-231
treated with 90 mM 5-FU were used as a
negative signal (minimal response for
maximal inhibition). Overall, 20 repli-
cates of each condition were included per
experiment, and the experiment was per-
formed on three different days. The mean
positive and mean negative signal – SD were used to calculate the Z-
factor.
Microscopy
Phase-contrast and fluorescent images were recorded using a
10 · UPlanFL objective (N.A. 0.30) on a CellM system with a
IX81 microscope (Olympus). For nuclei counting, MDA-MB-231
cells in the 96-well plate were fixed in 4% paraformaldehyde,
permeabilized with 0.5% Triton X-100 in D-PBS, blocked in 2%
bovine serum albumin (BSA; Sigma-Aldrich)/1% Glycine in
D-PBS, and stained with DAPI (Molecular Probes). The nuclei were
Table 1. Step-by-Step Protocol for XTT Assay on Cell Layers Embedded
in 3D Matrix in 96-Well Plates
Step Parameter Value Description
1 ECM solution 40mL/well desired ECM concentration
2 Thin (bottom) layer of ECM 100mL add to well and remove immediately
3 Incubation 15min 37C, 5% CO2
4 Seed cells 100mL 10,000 cells/100mL
5 Incubation time (adhesion) 2 h 37C, 5% CO2
6 Second (top) layer of ECM 40mL/well add ECM on top of cells
7 Incubation 30min 37C, 5% CO2
8 Growth medium 100mL add growth medium on top of ECM
9 Cell growth; drug incubation 24–48 h proliferation time
10 XTT labeling solution 50mL/well detection of metabolic active cells
11 Incubation time 3–4 h 37C, 5% CO2
12 Assay readout 450 and 620 nm absorbance measurement using ELISA reader
Step Notes
1. Prepare 1/3 extra of final volume needed, keep on ice.
2. This generates bottom ECM layer; recuperate ECM solution for use in step 6.
3. Polymerization of bottom ECM layer.
4. Cell density needs to be within determined linear range for each cell line used; useful test range 5,000–40,000
with 10,000 as recommended starting density; 2 or more replicates per condition; Include blank samples (no
cells or cells killed using 0.2% triton-X-100) for backgrond correction.
5. Adhesion of cells; adhesion time dependent on cell type.
7. Polymerization of ECM.
8. Add drugs of interest to the growth medium.
9. Cell growth time and drug incubation time should exceed cell type- and experimental setup-dependent
doubling time. Doubling time is determined in a separate experiment and is not identical in the 3D matrix
compared with the 2D culture. As indication: in 3D matrix-embedded cell layer: 36 h for MDA-MB-231 and HT-
1080.
10. XTT is reduced into a colored soluble formazan by metabolic active cells.
11. Incubation time may be varied depending on the cell number or cell type (as indication for adherent cells)
(10,000–20,000 cells/well), preferably < 6 h to prevent saturation
12. Absorbance= A450–620nm-mean(Ablank).
10–12. Performed at t0 and at endpoint time in parallel samples.
2D, two-dimensional; 3D, three-dimensional; ECM, extracellular matrix.
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manually counted using Cell Counter (ImageJ, http://rsbweb
.nih.gov/ij).
Statistical Analysis
Statistical analysis of the time courses showing proliferation ki-
netics was carried out using two-way analysis of variance followed
by a post-hoc test using Bonferroni adjustments (Graphpad Prism).
The EC50 values were statistically compared using a Student’s t-test
according to the Graphpad Prism guidelines. P values less than
0.05 were considered as indicating statistically significant differ-
ences. Data are generally expressed as mean – standard error of the
mean. In each experiment, multiple replicates per condition are
performed (2 £ n £ 8), and one (of two) representative experiment
is shown.
RESULTS AND DISCUSSION
Assay Conditions and Optimization for Measuring Cell
Proliferation in 3D Versus 2D Cell Layers; Performance
Comparison
We applied the one-step XTT-assay for quantifying cell numbers,
cell viability, and cell proliferation in cells grown in a 3D setup, that
is, those embedded in a dense matrix (collagen type I or Matrigel). We
detail the performance of the XTT-assay in these dense 3D matrices
compared with its classical use in cells grown on a 2D surface (‘‘2D
culture’’ on monomeric collagen coating) (Fig. 1A, left). In the 3D
setup used, the cells are embedded as a cell layer in the plane between
two collagen layers (3Dmatrix-embedded cell layer) (Fig. 1A,middle;
for details see Materials and Methods), which is distinct from ‘‘3D
matrix-embedded mixed cultures’’ in which the cells are dispersed as
single cells within the matrix (Fig. 1A, right). We specifically address
proliferation in the ‘‘3D matrix-embedded cell layer’’ format, because
this setup is highly compatible with measuring the invasive capacity
of cells using a 3D woundhealing-like assay in which the cells are
allowed to invade a central cell-free area (ORIS; Platypus Technol-
ogies). This assay is gaining interest for high-throughput screening of
2D migration39–41 and 3D invasion.42,43 We ultimately show that
measuring the effects of compounds on invasion and proliferation
under similar 3D conditions forms an asset in the in vitro charac-
terization and evaluation of cancer targeting drugs.
To demonstrate the quality of employing the XTT-assay in dense
3D matrices, we addressed different issues that are expected to vary
with cell type and assay format (3D vs. 2D). These include (i) cell
starting numbers (ensuring a linear response as well as an appropriate
signal over background), (ii) optimal XTT incubation time
Fig. 2. Cell proliferation kinetics differ in 2D culture and 3D matrix-embedded cell layer culture in a cell type-dependent manner;
optimization of XTT reaction time. (A–D) Cell proliferation kinetics. Cell proliferation expressed as a fold increase versus t0 based on the net
absorbance ratios Atx/At0 in a function of time. Error bars represent the SEM of two independent experiments; per experiment n = 8 for all
conditions; pair-wise comparison (post-hoc test) between different setups indicated by ***P < 0.001; **P < 0.01; *P < 0.05. MDA-MB-231 at
10,000 cells/well (A, solid and dashed line) and HT-1080 at 5,000 cells/well (B, solid and dashed line) were seeded as a 2D culture (solid
line) or a 3D matrix-embedded cell layer (2mg/mL collagen I; dashed line) or both were seeded as a 3D matrix-embedded cell layer (2mg/
mL collagen I) at 40,000 cells/well (A and B, dotted line). (C, D) MDA-MB-231 cells (10,000/well) (C) and HT-1080 (5,000/well) (D) seeded
in between two layers of Matrigel at 2 or 5mg/mL. (E, F) Influence of XTT incubation time on mean absorbance (A450–620) in 2D culture (E)
and in a 3D collagen-embedded cell layer setup (F) for MDA-MB-231 at a low (10,000 cells/well) and high (*20,000 cells/well, i.e., after
40 h of growth) cell density. Absorbances were measured after 2, 3, 4, 6, and 24 h of XTT incubation. Background signals (based on blank
samples) (dashed lines) and signals from the wells containing cells (solid lines) at a low (gray) and high (black) cell density are plotted.
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(preventing signal saturation), and (iii) proliferation rates and/or
doubling times (required before screening antiproliferative com-
pounds in a specific format).
To determine the linear range for the different 2D and 3D setups,
the cancer cell lines MDA-MB-231 or HT-1080 were seeded and al-
lowed to settle for 2 h before the addition of XTT at a wide range of
densities (5,000 to 50,000 cells/well) in 96 wells (Fig. 1B, C). For the
2D culture and for the cell layer embedded in 3D collagen type I
matrix, the net absorbance signal initially increases linearly with cell
number until *20,000–25,000 cells/well, and, subsequently, levels
off toward a maximum (Fig. 1B). We also extended the assay to a
different matrix, that is, Matrigel, representing a reconstituted
laminin-rich basement membrane. The cell number analysis of
MDA-MB-231 and HT-1080, embedded as a layer in Matrigel at a
concentration of 2 (Fig. 1C, dashed line) and 5mg/mL (solid line), is
similar as in the 3D collagen matrix with a linear increase in absor-
bance for the range of 5,000–20,000 cells/well. Figure 1D and E
documents the basis of the deviation from linearity. At cell densities
higher than 30,000 cells/well, confluency is reached in the 2D- and
3D layer-based setups (Fig. 1D). For the tested adherent cell types, the
limited surface available for cell adhesion determines the linear
range, as supported by the fact that the DAPI-based cell count was
only linearly correlated to the seeded cell numbers below *40,000
cells/well (Fig. 1E).
Together, this indicates that the useful range of cell numbers for
adherent cells is similar for the 3D matrix cell layer assay and in the
2D culture and is limited by confluent growth and well surface area.
Consequently, this range is lower than that for suspension cells
(Figure 3 in Company Application Note, www.roche-applied-science
.com).
Based on the experiments with MDA-MB-231 shown in Figure 1B
and C, we evaluated whether higher
background values—as might be ex-
pected in a dense 3D matrix—influence
the quality of the measurements. Since
background effects can only be judged
correctly by considering the variation in
response,38 we also calculated, in addi-
tion to S/B, the parameters that take into
account the variation on background (S/
N) or on both background and signal (as
in a Z-factor). Note that these calcula-
tions only provide details on signal to
background levels; see next for an
evaluation of the true dynamic range
using minimal and maximal signals af-
ter background correction. Despite the
fact that the S/B-values in 3D condi-
tions are generally smaller than in 2D
conditions (Table 2), the low variation in
the mean absorbances results in suffi-
ciently high S/N values (and Z-values
‡ 0.5) for nearly all the 3D conditions.
This indicates that, using XTT, the background in the 3D matrix-
embedded setup is not lowering the assay quality and that this quality
in the 3D matrix-embedded setup is comparable to that in the 2D
culture. If needed, cell numbers can be increased to optimize S/N
(compare values for 10,000 and 20,000 cells in Matrigel; Table 2).
Subsequently, we measured cell proliferation after 12, 24, 36, and
48 h for MDA-MB-231 (Fig. 2A, C) and HT-1080 (Fig. 2B, D) to
compare cell-specific doubling times in the different setups (2D and
3D) and matrices (collagen and Matrigel). This is important to select
assay times for drug screening. Proliferation kinetics of both MDA-
MB-231 and HT-1080 (10,000 and 5,000 cells/well seeded at t0, re-
spectively) are significantly slower in the 3D collagen-embedded
layer setup (dashed line) versus the 2D culture (solid line) (Fig. 2A, B).
Doubling (i.e., a proliferation fold vs. t0 equal to two) is reached at
least 12 h later in the 3D matrix-embedded layers than in the 2D
culture. As expected, based on the confluency shown in Figure 1D,
MDA-MB-231 and HT-1080 that are seeded at 40,000 cells/well in
the 3D collagen-embedded cell layer no longer showed proliferation
due to contact inhibition (Fig. 2A, B, dotted lined). Proliferation
kinetics of MDA-MB-231 and HT-1080 in 5mg/mL Matrigel are
comparable with those in 3D collagen embedded cultures, yielding a
fold change of 2 after 36 h (Fig. 2C, D, solid lines). Similar prolifer-
ation kinetics for MDA-MB-231 are observed in 2mg/mL Matrigel
(Fig. 2C, dashed line), whereas HT-1080 cells show faster prolifera-
tion kinetics in less dense Matrigel (Fig. 2D, dashed line). Similar to
reports using cells in 3D pseudo-culture, reports on the expansion of
stem cells, and in the field of regenerative tissue research,44–47 these
data agree with previous works that cell-ECM contact affects cell
proliferation and does so in a cell type-dependent manner.
In addition to the assay time, we compared the effect of varying the
time of the XTT reaction (XTT incubation times: 2–24h) in 3D versus
Table 2. Evaluation of Signal to Background Ratio’s in 2D and 3D Setups
Setup
No. of cells
(3103) S/Ba S/Nb Zc
2D culture 10 2.72 25.48 0.68
20 4.40 50.45 0.86
3D (cell layer embedded in collagen matrix) 10 1.87 76.47 0.63
20 3.50 220.97 0.48
3D (cell layer embedded in Matrigel [5mg/mL]) 10 1.75 34.29 0.68
20 2.60 72.90 0.78
3D (cell layer embedded in Matrigel [2mg/mL]) 10 1.87 24.45 0.49
20 2.66 46.71 0.78
aS/B= ms/mb, where ms is mean signal (450–620 nm) and mb is mean background (450–620 nm).
bS/N = (ms- mb)/SDb, where SDb is standard deviation of mb.
cZ = 1 - (3· [SDs+ SDb])/jms-mbj, where SDb and SDs are standard deviation of mb and ms.
S/B, signal-to-background; S/N, signal-to-noise.
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2D conditions. Figure 2E and F shows for MDA-MB-231 the net ab-
sorbance (A450–620) in function of XTT incubation time for background
samples and for samples with low and high cell numbers. Background
values (dashed lines) are only slightly affected by longer XTT incu-
bation time, and these are similar in 2D and 3D conditions. At high cell
numbers (Fig. 2E, F, black), saturation of the signal is already reached
at*6 h XTT incubation. For low cell numbers (Fig. 2E, F, gray), the
increase is at least linear up to 6 h of the XTT reaction, but after 24 h of
XTT incubation, the signal has no longer increased in a linear fashion.
These analyses indicate that an XTT incubation time of 3 to 4 h is
optimal to yield a linear response with cell number, and differences are
hardly observed for 2D and 3D conditions. A longer (6–24h) XTT
incubation time may only be used for low cell numbers (or for cell
types with apparent low metabolic activity; see Figure 3 in Company
Application Note, www.roche-applied-science.com).
In summary, we demonstrate the equal applicability of the XTT-
assay for measuring cell growth in a 3D matrix-embedded cell layer,
as compared with 2D cultured cells. Measurements are possible in the
two most commonly used dense 3D matrices (collagen gel [2mg/mL]
and Matrigel [2 and 5mg/mL]). The background of 3D samples does
not affect the quality of the measurements. However, a different
optimization is required for different culture conditions (2D, 3D,
matrix type, and cell type), especially with regard to signal linearity
versus cell number and cell doubling time. Significantly, the differ-
ences observed in cell proliferation kinetics in 2D cultures versus 3D
matrix-embedded cultures indicate the potential benefit of measur-
ing cell growth in 3D matrices.
Measuring Compound Effects in 3D Versus 2D Conditions
We further validated proliferation measurements in the 3D setup
by evaluating the effect of compound treatment on cell growth and
viability and by comparing them with the effects on cells grown in
2D. Proliferation folds (Atx/At0) are plotted in semi-log dose response
curves as ‘‘% cell viability’’ versus drug concentration (Fig. 3; see
Fig. 3. Dose-dependent inhibition
of cell proliferation on drug treat-
ments in 3D versus 2D conditions.
(A–F) MDA-MB-231 and HT-1080
cells were seeded at a low cell
density (10,000 and 5,000 cells/
well, respectively) in 2D cultures
(black lines, circles) and 3D matrix-
embedded cell layers (gray lines,
triangles) and were left untreated
(control) or drug treated. Cell pro-
liferation was measured after 48h
(MDA-MB-231) or 44h (HT-1080),
and the fold increase versus t0
(Atx/At0) of the control (untreated)
samples was set to 100% viability.
Symbols in red indicate the % vi-
ability corresponding with Atx/
At0< 1, that is, indicating toxicity
(see also Materials and Methods).
The error bars represent SEM;
n=4 for each dilution; experi-
ments were repeated twice, and
one representative experiment is
shown. (A, B) Biphasic semilog
dose-response curves of MDA-MB-
231 (A) and HT-1080 (B) cells
treated with a 1.33 serial dilution
of 5-FU using a starting concen-
tration of 90mM. (C, D) Four-
parameter semi-log dose-response
curves of MDA-MB-231 (C) or
HT-1080 (D) cells treated with a
1.33 serial dilution of IPA 3 using a
starting concentration of 120mM.
(E, F) Four-parameter semi-log
dose-response curves of MDA-
MB-231 (E) and HT-1080 (F) cells
treated with a 1.33 serial dilution
of y-27632 using a starting con-
centration of 400mM. 5-FU, 5-
Fluorouracil.
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Materials andMethods for details). This approach allows, in principle,
the determination of EC50 values (defined as the concentration of the
drug at which 50% of the effect is obtained), indicative of an anti-
proliferative (cytostatic) or cytotoxic effect or, where applicable, for
both effects individually.
We first tested the effect of dFUR, which is metabolized into its
active form, 5-FU, on MDA-MB-231 and HT-1080 (10,000 and 5,000
cells seeded per well, respectively). This compound is widely used in
anti-cancer chemotherapy.48,49 We observe biphasic dose-dependent
inhibition of cell growth for MDA-MB-231 (Fig. 3A) and HT-1080
(Fig. 3B), in both 2D culture (black line, circles) and 3D matrix (gray
line, triangles). The first phase of the curve shows a dose-dependent
antiproliferative effect. In the second phase, the ratios of measured
cell number versus cell number at the start (*Atx/At0) are smaller
than 1 (presented in figure by red symbols), indicating dose-depen-
dent toxicity. This second phase is more gradual for HT-1080 in 3D.
We derive two EC50 values characterizing each dose-response curve
(except for the second phase for HT-1080 in 3D). For MDA-MB-231,
both EC501 and EC502 are significantly smaller for cells in the 3D
matrix than those in the 2D culture (P< 0.05, factor 2, Fig. 3A); in
addition, for HT-1080, the EC501 value is lower in the 3D matrix than
in the 2D culture (P < 0.05, Fig. 3B). In addition, the EC501 values
indicative of a cytostatic effect are in the high nM-low mM concen-
tration range, whereas obvious cytotoxic effects (*EC502) require a
drug concentration that is approximately 10-fold higher.
These results demonstrate a different (i.e., two-fold higher) sen-
sitivity to the cytostatic activity of 5-FU in the 3D collagen-
embedded cell layer setup versus the culture on a 2D monomeric
collagen coating in the tested cell lines. This underlines the potential
benefit of scoring drug effects on cell proliferation measurements
within a 3D matrix.
We used the effect of 5-FU to further investigate the dynamic
range, reproducibility, and overall quality of the assay in 3D versus
2D conditions. We performed three measurements on different
days to compare the effect on the 2D culture and the 3D matrix-
embedded-layer setup on untreated MDA-MB-231 (maximal sig-
nal, no inhibition) and on MDA-MB-231 treated with 90 mM 5-FU
(used as minimal signal, maximal inhibition). The Z-factors, de-
rived as described earlier,38 for both the 2D culture and the 3D
matrix-embedded cell layer setup (0.928 and 0.819, respectively,
Table 3) are well above the critical Z-value of 0.5, demonstrating
that, in the 3D matrix-embedded cell layer approach, the assay
quality is high and the dynamic range is comparable to that in the
2D culture.
Asmentioned previously, the 3Dmatrix-embedded cell layer setup
is highly suitable for testing the invasive capacity of cells. Anti-
invasive drugs may or may not affect cell proliferation, or may dis-
play identical or different dose dependency for anti-invasion or
antiproliferation. The application of the XTT-assay in this experi-
mental 3D setup described here that is also suited for invasion
analysis allows the testing of these multiple aspects. As an illustra-
tion, we evaluated the effect on the proliferation of two compounds
known to inhibit key molecules in the signals driving amoeboid or
mesenchymal cell migration and invasion,50 namely inhibitors
against ROCK or against PAK.
Compound IPA 3 targets the auto-regulatory mechanism of group I
PAKs that are possible targets in cancer therapy as a consequence of
their role in cell proliferation, morphogenic processes, and cell motil-
ity.51–53 A concentration range of IPA 3 (up to 120 mM) was admin-
istered to MDA-MB-231 and HT-1080 cells, in 2D culture, or to the
cell layer embedded in 3D collagen. For MDA-MB-231, this results in
an inhibition of cell viability with very similar dose responses for 2D
and 3D (EC50 values*20 mM) (Fig. 3C). At EC50 or higher doses, the
cell numbers after drug treatment are lower than those initially
seeded (Atx/At0 < 1), indicating toxicity. Although the EC50 values for
HT-1080 cells are in the same range as for MDA-MB-231, HT-1080
are slightly less sensitive to IPA 3 in a 3D matrix-embedded cell layer
(EC50 = 26.2 mM) compared with 2D (EC50 = 19.9 mM) (P < 0.05, Fig.
3D). In addition, compared with MDA-MB-231, the effect is cyto-
static rather than cytotoxic in the tested concentration range (Fig. 3C,
D). In comparison, for these cells and using the same experimental 3D
setup, this compound typically already displays a significant inhi-
bition (40%) of invasion of the matrix embedded cell layer in a
central cell-free zone at lower concentrations (5 mM) (Huyck et al.,
data not shown).
As shown in Figure 4, 10 mM of the ROCK inhibiting compound y-
27632 yielded in the 3D matrix-embedded cell layer format more
than 50% invasion inhibition; a similar inhibition is obtained for HT-
1080 cells (not shown). However, at this drug concentration, cell
growth—measured in the same experimental 3D setup—is completely
Table 3. Dynamic Range of Proliferation Assay
in 3D Matrix Versus 2D Culture
Untreated
(maximal signal)
5-FU treated
(minimal signal)
2D
Meana 1.350 0.199
SD 0.023 0.005
Zb 0.928
3D
Meana 0.593 0.133
SD 0.021 0.007
Zb 0.819
aMean of three experiments performed on three different days (n = 20 per
condition in each experiment)
bZ= 1 - (3· [SDmax+ SDmin])/jmmax- mminj, where mmax is mean maximal
signal (450–620 nm), mmin is mean minimal signal (450–620 nm), mmax, mmin:
background corrected, SDmax is SD maximal signal, and SDmin is SD minimal
signal.
5-FU, 5-Fluorouracil.
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unaffected (Fig. 3E, F). Tenfold higher concentrations of this drug are
required to induce inhibition of MDA-MB-231 growth and toxicity in
the 3D matrix as demonstrated by an EC50 of 137 mM (Fig. 3E). For
HT-1080 cells in the 3D matrix-embedded setup, a drug effect (tox-
icity) is even not observed until a concentration of 300 mM or higher
is achieved (Fig. 3F). In contrast to the low response in the 3D setting,
proliferation in the 2D culture of MDA-MB-231 and, especially, of
HT-1080 is more sensitive to ROCK inhibition: a gradual dose-
dependent inhibition is observed, although even at 400 mM (the
highest concentration tested), a maximal effect was not yet reached
(Fig. 3E, F). Rho and ROCK have generally been linked to prolifera-
tion and cell survival in diverse cell lines, a.o. based on their role in
integrin-based adhesion complex formation and in their control of
cyclin and cyclin-dependent kinase expres-
sion.54–56 The ECM is known to provide cells
with both chemical and mechanical cues a.o.
via FAK-Rho-Erk signaling and Rho-ROCK-
actomyosin contractility,57 and these cues are
substantially different in 2D versus 3Dmatrix.58
Given the difference in sensitivity of HT-1080
proliferation to ROCK inhibition in 2D versus
3D, it will be of interest to determine whether
the extent of adhesion and of ROCK-dependent
activation of key proliferation factors differs in
the 2D versus 3D conditions. This example of
drug effect further documents the different re-
sponses when drug-treated cells are cultured in
2D or 3D conditions and, in addition, the im-
portance of testing different cellular properties
(in casu invasion and proliferation) in the same
experimental setup. Based on the analyses in
the 3D matrix, y-27632 can be viewed as a drug
that acts purely as an anti-invasive agent in
MDA-MB-231 and HT-1080 at low doses (lower
mM range) and only becomes toxic to the cells
at, at least, 10-fold higher concentrations.
CONCLUSIONS
This article, in which we employed a 3D setup
in which a cell layer is fully matrix embedded,
establishes that proliferation measurements in
dense 3D matrices using the one-step XTT
proliferation assay are as easy as and qualita-
tively equal to current approaches in 2D culture
(and, by extrapolation, in porous 3D scaffolds).
As such, this article will accelerate wider ap-
plication of this 3D approach, which is strongly
suggested as yielding more physiologically
relevant answers. Using a quality comparison of
measurements conducted on cells embedded in
a dense 3D matrix versus cells in 2D, we show a
similar dynamic range and no negative effects
of background. The assay allows the measuring
of cell-type specific proliferation kinetics and antiproliferative, cy-
tostatic, and cytotoxic effects of compounds in different dense 3D
matrices (collagen, Matrigel). We show that cell growth and drug
sensitivity in a 3D matrix are not necessarily identical as in a 2D
culture, and these differences do not follow a predictable pattern but
are cell type- and compound-dependent. Although the higher pre-
dictability of results obtained in 3D matrices still needs confirmation
in vivo, the observed differences already suggest a possible benefit of
(also) screening in more complex in vitro conditions. Moreover, by
validating proliferation measurements in the 3D matrix-embedded
cell layer setup that is compatible with invasion measurements, the
drug effects on proliferation and invasion can be more reliably
compared. This results in a more optimal in vitro drug
Fig. 4. 3D matrix-embedded cell layer invasion is inhibited at low doses of y-27632. MDA-
MB-231 cells were seeded as a 3D matrix-embedded cell layer (2mg/mL collagen) with a
central cell-free area (according to ORISTM cell invasion assay; Platypus Technologies)
and were allowed to invade for 36 h. (A) Phase-contrast images of MDA-MB-231 after 36 h
invasion. MDA-MB-231 were left untreated (left) or treated with 10 mM y-27632 (right).
The dashed line indicates the edge of the peripheral cell layer at start (time 0); the solid
line indicates the edge of the cell layer after 36 h of invasion. Scale bar = 200 mm. (B)
Invasion efficiency for untreated and y-27632 treated cells. The change in the area of the
cell layer was measured at different time points, and the velocity of the area increase was
calculated. The increase over time in the area of the untreated cells was set to 100%
invasion. The error bars represent SEM; n = 6.
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characterization. This validated protocol in the 3Dmatrix, thus, holds
promise for improving early-stage, high-throughput drug screening
for targeting—by individual drugs or by combinations—both highly
invasive and highly proliferative subpopulations of cancers. The
validation of the assay is established here in collagen and Matrigel,
but may also prove useful in microporous synthetic ECM mimics or
nanofibrous scaffolds with bio-inspired cell-instructive and de-
gradable properties that are being developed.16,59
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